Gene Therapy For Mesothelioma
First Claim
Patent Images
1. A method of treating a human patient diagnosed with mesothelioma resistant to, or recurrent after, an anti-folate and platin combination first-line treatment regimen, the method comprising:
- treating said patient with a second-line treatment regimen comprising;
(i) an agent which induces the expression of interferon, in an amount effective to induce interferon expression in a human, and (ii) pemetrexed and (iii) celecoxib.
3 Assignments
0 Petitions
Accused Products
Abstract
Gene therapy based combination therapy for malignant pleural mesothelioma (“MPM”) that is resistant to or recurrent after chemotherapy employing a viral vector containing a human interferon transgene, followed by standard first- or second-line cytotoxic chemotherapy. Overall survival rate was significantly higher than historical controls in the second-line group.
-
Citations
30 Claims
-
1. A method of treating a human patient diagnosed with mesothelioma resistant to, or recurrent after, an anti-folate and platin combination first-line treatment regimen, the method comprising:
treating said patient with a second-line treatment regimen comprising;
(i) an agent which induces the expression of interferon, in an amount effective to induce interferon expression in a human, and (ii) pemetrexed and (iii) celecoxib.- View Dependent Claims (4, 5, 6, 7, 8, 9, 10, 11, 12, 20, 21, 22)
-
2. (canceled)
-
3. (canceled)
-
13-19. -19. (canceled)
-
23. A method of treating a human patient diagnosed with mesothelioma, the method comprising:
- administering celecoxib, pemetrexed, a platin chemotherapeutic and an agent which induces the expression of interferon.
- View Dependent Claims (24, 25, 26, 27, 28, 29, 30)
Specification